Note 7 - Licenses, Royalty, Collaborative and Contractual Arrangements (Tables)

9 Months Ended

Mar. 31, 2017

Notes Tables

Schedule of Segment Reporting Information, by Segment [Table Text Block]

	Three Months Ended March 31,
	2017		2016
	(in millions)
Royalty revenue - Relenza ®	$	1.1	$	1.7
- Inavir ®		3.0		3.6
Non-cash royalty revenue related to the sale of future royalties		0.8		-
Total revenue	$	4.9	$	5.3

	Nine Months Ended March 31,
	2017		2016
	(in millions)
Royalty revenue - Relenza ®	$	2.7	$	4.5
- Inavir ®		3.1		4.3
Non-cash royalty revenue related to the sale of future royalties		3.0		-
Total revenue	$	8.8	$	8.8